Success Metrics

Clinical Success Rate
85.7%

Based on 18 completed trials

Completion Rate
86%(18/21)
Active Trials
0(0%)
Results Posted
44%(8 trials)
Terminated
3(13%)

Phase Distribution

Ph phase_3
3
13%
Ph phase_1
3
13%
Ph phase_4
3
13%
Ph phase_2
3
13%

Phase Distribution

3

Early Stage

3

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
3(25.0%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 3Large-scale testing
3(25.0%)
Phase 4Post-market surveillance
3(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

18 of 21 finished

Non-Completion Rate

14.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

24

all time

Status Distribution
Completed(18)
Terminated(3)
Other(3)

Detailed Status

Completed18
Terminated3
unknown3

Development Timeline

Analytics

Development Status

Total Trials
24
Active
0
Success Rate
85.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (25.0%)
Phase 23 (25.0%)
Phase 33 (25.0%)
Phase 43 (25.0%)

Trials by Status

terminated313%
unknown313%
completed1875%

Recent Activity

Clinical Trials (24)

Showing 20 of 24 trialsScroll for more
NCT00224393Phase 2

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

Completed
NCT04559412Phase 1

Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis

Unknown
NCT04398732

Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients

Completed
NCT04428411

Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Completed
NCT04428502

Study To Evaluate The Impact Of Anti-Cyclic Citrullinated Peptide(Anti-CCP) For Management With Enbrel In Patients With Psoriatic Arthritis(PsA)

Completed
NCT04428424

Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients

Completed
NCT03100734

Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel

Completed
NCT04079374Phase 3

Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel

Unknown
NCT02481180Phase 1

Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)

Terminated
NCT01934933Phase 4

Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis

Completed
NCT01891864Phase 3

Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel

Completed
NCT02357069Phase 3

A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Unknown
NCT01421303

Work Productivity in Active Ankylosing Spondylitis (AS) Patients Treated With Enbrel.

Completed
NCT01411215

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Terminated
NCT00111124Phase 4

Enbrel® in Psoriatic Arthritis

Completed
NCT00078793

Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis

Completed
NCT00127387Phase 2

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

Terminated
NCT01188655

Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis

Completed
NCT00116727

Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Completed
NCT01145950Phase 1

Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25 mg With Those of Enbrel®

Completed

Drug Details

Intervention Type
DRUG
Total Trials
24